RBC Capital maintains Viracta Therapeutics at 'outperform' with a price target of $7.00 May 9, 2023 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:MultiPlan Corp. Acquires Leading Healthcare Data and Analytics Firm Benefits Science LLC Back: All Posts Next:RBC Capital maintains Taskus at 'outperform' with a price target of $21.00